To compare 2 types of standard care radiation treatment: photon and proton, to find out which type is best for treating non-metastatic breast cancer.
To compare the good and bad effects in terms of patient life span after these 2 different types of radiation therapy (photon versus proton) in combination with FDA-approved chemotherapy for lung cancer. This study will allow the researchers to know whether the proton therapy approach is better, the same, or worse then the usual photon approach in terms of survival.
To collect granular information on cancer patients infected with COVID-19.
To assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab monotherapy or placebo as adjuvant therapy. This study will be conducted in patients with HCC who are at high risk of recurrence after curative hepatic resection or ablation. 888 patients will be enrolled globally.
To collect & analyze information on people with similar cancer diagnosis. The effectiveness of procedures & treatments, the usefulness of various tests, and the incidence of short or long-term side effects will be evaluated. The ultimate goal is to improve effectiveness of treatments & procedures & limit side effects & late complications for patients.
Determine the efficacy and safety of dostarlimab plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel in patients with recurrent or primary advanced (Stage III or IV) endometrial cancer.
To compare the efficacy of TACE with Duravalumab + Bevacizumab, TACE with Duravalumab alone and TACE only.
The treatment of participants with newly diagnosed, high-risk EC following surgery with curative intent.
To obtain information on the safety & effectiveness of the NovoTTF-100M (study device) in patients with brain metastases (tumors) from non-small cell lung cancer.
To examine how multiple myeloma is treated by doctors all over the world, how people respond to these treatments, & the economic impact of these treatments
To compare the progression-free survival (PFS) of patients with Stage III or IV ovarian cancer treated with platinum-based therapy, TSR-042, and niraparib to standard-of-care (SOC) platinum-based therapy.
To determine whether the addition of atezolizumab to chemotherapy and bevacizumab improves overall survival compared to chemotherapy plus bevacizumab in patients with metastatic persistent or recurrent carcinoma of the cervix
To determine if prostate cancer patients treated with proton therapy, as compared to IMRT, experience:
Improved quality of life
Reduced toxicity
Non-inferior or even superior cancer control
To determine if Hypofractionated proton therapy is non-inferior to standard fractionated proton therapy in patient-reported outcomes & physician-reported toxicity.